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SPECIAL ISSUE 
Introduction 
Diagnostics, Medical testing, and Value in  
Medical Anthropology 




The process of diagnosis—assigning an individual with illness to a standard 
disease category—is foundational to modern biomedicine. As numerous 
anthropologists, sociologists, and medical historians have shown, diagnosis is also 
fundamentally a social and cultural practice (Blaxter 1978; Brown 1990; Rosenberg 
2002; Jutel 2009, 2015). Diagnostic categories and processes are central to the 
production and distribution of biomedical authority (Armstrong 2011; Rosenberg 
2002). A recognised diagnosis confers legitimacy on the patient’s status as ‘sick’ 
and mediates access to support and resources (Jutel and Nettleton 2011; Petryna 
2013; Price this issue). It can be both a form of social control (Brown 1990) and 
the basis for new solidarities and subjectivities (Rose and Novas 2005). Diagnosis 
is also a contested domain, both because of the uncertainties that are integral to 
the process of fitting an individual case into a universal category, and due to social 
and political contestation over the meaning, content and implications of particular 
disease categories—or their absence (Nettleton, Kitzinger, and Kitzinger 2014; 
Pickersgill 2014; Smith-Morris 2015).  
Until recently, the burgeoning field of anthropology and sociology of diagnosis has 
focused on diagnosis as primarily a process of classification and labelling (e.g., 
Brown 1990; Jutel 2009; Jutel and Nettleton 2011; Armstrong 2011; Smith-Morris 
2015; Manderson 2020). The contributions to this special issue, by contrast, focus 
on the relationship between diagnosis and the technical processes of testing that 
inform it. The in vitro investigation of biological specimens taken from the human 
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body has, as medical historians often remind us, long been a hallmark of modern 
medicine (Ackernecht 1967; Cunningham and Williams 1992; Armstrong 2011; 
Löwy this issue). Alongside the rise of pathological anatomy, the emergence of 
laboratory medicine in Europe in the late nineteenth century helped to consolidate 
the shift in medical cosmology from ‘bedside medicine’, which defined disease in 
terms of its ‘external and subjective manifestations’, to ‘hospital medicine’, in which 
expert investigators identified hidden pathogens as the cause of patient illness and 
categorised those pathogens as objective disease entities (Jewson 1976). With 
these transformations, according to Jewson, ‘medical practise became an 
appendage to the laboratory’ (1976, 230). While other medical historians have 
provided a more nuanced picture of the emergence of modern medicine in the 19th 
and 20th centuries, it is difficult to dispute the fact that laboratory testing has come 
to occupy a central place in contemporary medical epistemologies, interventions, 
and practices.  
Laboratory medicine, of course, only travelled as far as testing infrastructure would 
take it, a point often overlooked by historians of European medicine (Street 2018). 
Nonetheless, the fundamentals of laboratory investigation are included in medical 
education syllabi worldwide as essential tenets of medical practice. Having blood 
drawn is a common feature of a visit to the doctor, maternal health clinic, or hospital 
in at least the well-resourced pockets of most health systems. Point-of-care tests 
for infectious diseases such as malaria, HIV and other sexually transmitted 
infections, and for emerging viruses that cause diseases such as COVID-19, are 
increasingly available—often for private purchase and self-administration—in 
places where laboratory infrastructure is lacking. Concerns about spiralling drug 
prices, antimicrobial resistance and emerging disease outbreaks have all 
contributed to heightened awareness of the need for accurate and accessible 
diagnostic testing in global health (Chandler 2019; Pai et al. 2012). By virtue of 
studying people’s everyday engagements with medical systems, anthropologists 
therefore frequently encounter medical tests—whether in the form of biological 
samples, laboratory assays, material devices, or medical records—even if they 
have not always been the focus of our attention.  
Some key domains of pioneering scholarship provide a way of navigating the 
socio-material particularities and peculiarities of medical testing. Work on the 
gendered moralities of reproductive and newborn testing, for instance, has shown 
that tests can generate more uncertainty than they resolve, bring with them new 
burdens of responsibility, and open up raw emotional terrains (e.g., Birenbaum-
Carmeli and Inhorn 2009; Timmermans and Buchbinder 2010; Rapp 2000). 
Elsewhere, research on the rise of genetic testing since the early 1990s has 
explored the shaping of risk-based subjectivities and the emergence of the ‘patient-
in-waiting’ figure (e.g., Latimer 2007 Konrad 2003; Nelson and Robinson 2014). 
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And anthropological studies of point-of-care testing in so called ‘resource-poor’ 
settings have drawn attention to the values and assumptions embedded in the 
design of testing technologies, showing that in order for ‘simple’ technologies to 
work, there is often the requirement for the presence of the very same 
infrastructures that new rapid and portable testing technologies promised to 
replace (Beisel et al. 2016 Beisel, Calkins, and Rottenberg 2018; Engel and 
Krumeich 2020; Harper and Khatri 2019; Hutchinson et al. 2015, 2017; Kameda et 
al. 2021; Lee and Palmer 2018; Meinert et al. 2009; Palmer et al. 2020; Street 
2011, 2018; Whyte, Whyte, and Kyaddondo 2018).  
Despite the richness of these accounts, these threads of enquiry have tended to 
remain conceptually disparate, split among critical sub-communities and between, 
on the one hand, research focused on high-end laboratory-based technologies in 
high-income settings and, on the other, research focused on more frugal testing 
technologies designed for under-resourced health systems. The anthropology of 
medical testing has never quite flourished as a comparative field in its own right in 
the same way as has, for example, the anthropology of pharmaceuticals (Biehl 
2004; Dumit 2012; Ecks 2005; Nguyen 2010; Petryna, Lakoff, and Kleinman 2006; 
Whyte, van der Geest, and Hardon 2003). The anthropology of medical testing, in 
other words, already exists. But further work is required to consolidate this 
research into a field of enquiry: to reflect on what we already know, develop a 
common analytical vocabulary, and establish fertile lines of exploration for the 
future. Key questions for such an endeavour include how socio-material processes 
of testing shape the work and effects of diagnosis, and, more broadly, what tests 
and testing do in and to social and medical worlds.  
An impetus for greater consolidation and synthesis came in March 2020, when Dr 
Tedros Adhanom Ghebreyesus, Director-General of the World Health 
Organization, insisted that the world ‘Test, test, test’ in response to the rapid global 
spread of a novel and deadly coronavirus (WHO 2020). The epistemological 
stakes of testing for the SARS-CoV-2 virus that causes COVID-19 disease could 
not be higher: the effectiveness of infection control, clinical triage, scientific 
developments, economic strategy, and public acceptance all hinged on the 
accuracy of diagnosis. ‘Without testing’, Dr Tedros put it, ‘you are blindfolded’. The 
challenges of regulating novel technologies in public health emergencies 
underscored the complex moral values and fiscal virtues associated with 
diagnostic innovation, raising cross-cutting ethical questions from those around 
access, to those of safety, and of commercialisation (Kelly et al. forthcoming). The 
fragility of the trust placed in those providing testing and/or technologies, and the 
dependence of epidemic response on public ‘compliance’ with self-isolation 
guidelines in the case of a positive test result, opened a new frontier of 
consideration around the politics of diagnostic access and credibility. A similar 
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opening occurred, too, around the pragmatics of diagnosis: for whom and to what 
end was it taking place? (cf. Brhlikova et al. 2011).  
Since Dr Tedros made those comments, testing has seldom been far from the 
public consciousness, particularly in places where the virus has hit the hardest. In 
many countries, including the UK, a stuttering start to the response—characterised 
by swab scarcity, uncertain regulation, and accelerated product development—
has been followed by a proliferation of public testing centres, mobile surge-testing 
units, and private event or travel testing companies. They offer a plethora of testing 
technologies that target different biomarkers, use distinct sampling methods, come 
in a variety of physical formats, and are associated with fluctuating levels of 
accuracy (see also Beaudevin et al., and Löwy, both in this issue). Perhaps the 
most striking aspect of the ‘new normal’ for people living in these countries is the 
sheer ubiquity of COVID-19 medical testing. In the UK, for example, members of 
the public with no medical background or laboratory training now routinely keep 
rapid test ‘kits’—comprising sample swabs, bottles of buffer, test cartridges, and 
waste bags—in their kitchen cupboards, ready to lay out on a pre-cleaned surface 
at the slightest tingle of a sore throat.  
‘Tests are everywhere, aren’t they?’ one of our primary-school-aged children 
observed to us recently. ‘Well’, goes the intuitive anthropological response, 
‘everywhere here’. In fact, the ubiquity of testing in high-income countries afflicted 
by high case rates only makes the scarcity of testing systems in many low- and 
middle-income countries starker (Kelley et al. 2020; Munharo et al. 2020). Such 
testing disparities are also reflected in the distribution of social research into 
COVID-19 testing, with the vast majority of studies on the topic focusing on high-
income countries in the Global North (Bevan et al. 2021). Moreover, the fact that 
COVID-19 has brought the ethics and politics of medical testing to public attention 
does not mean medical testing was not already ‘everywhere’ before—only that, 
perhaps, it had less public visibility as a social, political, economic, and ethical 
‘problem’.  
The sociocultural significance of practices of testing and of medical tests 
themselves have taken centre stage during the COVID-19 pandemic. Taking the 
immediate prominence of medical testing in the pandemic response as a 
provocation, MAT put out an open call for papers on medical testing, diagnosis, 
and value in May 2020. Our goal was to render explicit a latent field of 
anthropological research by exploring how studies of medical testing in diverse 
social and cultural settings might speak to one another conceptually and 
empirically. We were open about what might come within the purview of the topic, 
and ultimately included papers on the development of new diagnostic platforms 
and on testing data practices in addition to more classical medical anthropology 
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research into the deployment and use of medical tests in diagnostic processes. If 
medical anthropology is to make a meaningful contribution to our understanding of 
the new world of COVID-19 testing, then it must also look beyond the current 
pandemic to consider what the anthropology of testing has to offer in terms of 
furthering our understandings of medical testing as a social and cultural process 
more broadly. This, we argue, is a fundamentally comparative, ethnographic 
project. 
In the remainder of this introduction, we elaborate on several themes that we 
identified as cutting across the ethnographic contributions to this special issue and 
which will, we hope, serve as prompts and provocations for future comparative 
work on the anthropology of medical testing. These themes include: the uneven 
geographies and unstable infrastructures of medical ‘testscapes’; the relationships 
between testing and governance; the commoditisation of tests and the 
transformation of the value of testing in global health markets; and the relationships 
between medical tests and scientific, social, and ethical uncertainty. In the final 
section, we return to the question of what diagnostic tests do and argue for a 
pragmatic anthropology that focuses on who benefits from testing and what forms 
of ‘public good’ they produce. 
Testscapes 
For a start, an ethnographic approach to medical testing involves noticing the 
places where medical testing is not taking place and where testing products are 
absent. The geographical unevenness of testing follows the well-worn contours of 
inequities between the Global North and South (Okeke 2018; Wilkinson 2017). For 
instance, in this issue Bunkley examines the relationship between testing and 
diagnosis, showing that widespread scarcity of glucometers in Senegal, and weak 
disease reporting systems, contribute to the obfuscation of both the scale and type 
of diabetes in the country. Here the ‘gold standard diagnosis’ is based either on a 
fasting plasma glucose test or on an A1c glucose test, both of which require costly 
and time-intensive laboratory work and remain out of reach for most. By narrowing 
the epidemiological imagination of the scale and nature of disease in Senegal, this 
absence of diagnosis also inhibits global health investment in effective measures 
of disease detection and control.  
A similar set of disjunctures animates Vernooij’s descriptions of the improvisation 
work performed by laboratory technicians to stabilise unstable equipment in the 
clinical laboratory of a Sierra Leonean hospital. Here, we see how the ‘diagnostic 
moment’ (Jutel 2015; Smith-Morris et al. 2021; Bunkley, this issue) is attenuated 
by infrastructural instabilities: the unstable supply chains, electrical outages, 
malfunctioning equipment, and poorly paid laboratory staff. In Vernooij’s article and 
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in the Field Note co-authored by Bah, Vernooij, and Street, diagnosis is a 
considerable achievement, made possible by investment of ‘entrepreneurial staff’ 
who privately procure materials to fill in the gaps, a charge which they offset by 
covertly charging patients for results. In a radically patchy diagnostic landscape, 
laboratory work often remains hidden and under-valued, but the meanings and 
value of medical tests for the people who conduct them can have far-reaching 
implications for patients. 
However, if 2020 has taught us anything it is that the absence of testing is not only 
an issue for low- and middle-income countries. Beaudevin et al. examine the ways 
in which the ‘scarcity’ of testing infrastructure at the start of the outbreak in France 
framed possible responses to the COVID-19 pandemic and ultimately led to the 
decision to resort to lockdown. Attending to the varied ways in which diagnostics 
worked in practice—as, alternately, public health and clinical tools—the authors 
complicate a straightforward and highly politicised discourse of scarcity, pointing 
instead to the specific sites where testing could be carried out, examining by whom 
and for what purpose. Despite their testing capacities, private laboratories were 
excluded from a national response since they lay outside both the socio-technical 
networks that have circumscribed France’s pandemic response, and the nation’s 
fragmented institutional jurisdictions. These two systems exist under continual 
threat from fiscal constraints and administrative reconfigurations and determine 
how infectious disease control takes place. Material scarcities, while real, are 
amplified and refracted by divergent testing terrains which do not mirror the 
territory of the nation state, seeding a governmental il-logic that remains 
entrenched in France’s pandemic response, even after tests have become widely 
available. 
Testing governmentalities 
Several of the contributions to this issue explore the interstices of testing and 
governance. For Beaudevin et al., the complex discourses and realities of testing 
scarcities provide a map of governmental deficiencies that are only amplified in an 
emergency. In their account, tests entail political risks, as diagnostic targets are 
missed and fail to do the work expected of them in opening up the economy 
following national lockdown (see also Boswell 2020). Kameda’s analysis presents 
a compelling counterexample of how testing capacity can actually generate a 
national imaginary. Kameda explores national efforts to develop blood bank tests 
as an exercise in sovereignty, one that requires a robust national imaginary to 
sustain. Kameda’s account underscores the political value of diagnostic 
infrastructure, showing how government-built molecular tests create the conditions 
of Brazil’s technological sovereignty.  
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Other contributions draw more explicitly on a Foucauldian frame of reference to 
explore the role of medical tests as technologies of governance and tools of 
subjectification. The contributions by Chowdhury and Basu and by Price both show 
that the bureaucratisation of medical testing (which enables testing to be deployed 
as a technology of governance) depends on the elision of nuance in test results 
and the erasure of subtle differences in their biological meaning. During the 
COVID-19 pandemic in India, as Chowdhury and Basu discuss, testing databases 
became the basis for a form of ‘government by database’ which, ultimately, led to 
a focus on the maintenance of the database itself as opposed to the maintenance 
of public health. In a similar vein, Price shows how the incorporation of COVID-19 
tests into legal apparatus for determining the right to work in the United States 
gave rise to a form of ‘diagnostic citizenship’ in which test results become 
bureaucratic instruments that are divorced from any medical significance they 
might possess. 
The contributions from both Löwy and Whitacre are concerned with the politically 
and ethically problematic status of the ‘asymptomatic carrier’ of infectious disease 
in public health governance. As Löwy demonstrates, the category rises with the 
dawn of laboratory testing and, with it, new and highly fraught capacities of public 
health governance. She shows how the persona of the asymptomatic carrier 
embodies the entrenched tensions between the liberty of the infectious-yet-healthy 
and the prophylactic exigencies of public good in an outbreak. Whitacre likewise 
explores the history of HIV testing in the US and in global health, showing how 
public health and legal mandates sought to strike a balance between the value to 
public health of people disclosing their positive HIV test result, and the right to 
privacy of the individual. These competing elements ultimately gave rise to a whole 
field of HIV public health research premised on the confessional practices 
(including diagnostic disclosure) of research subjects.  
Through a comparative history of typhoid, HIV and COVID-19, Löwy shows how 
public health responses to this conundrum of the asymptomatic carrier, who is not 
sick themselves but represents a threat to others, have consistently played out in 
ways that reinforce racial and class inequalities. In infectious disease control, 
testing not only differentiates diseases, but also the infectious from the non-
infectious, highlighting the role of tests as a technology of government and as a 
mechanism for social division. 
Testing markets 
Kameda’s work in this issue shows that the test is the outcome of an innovation-
driven economy. One set of value contestations plays out along tensions between 
the value that diagnostic tests hold for people as commercial products and their 
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value for people’s health. Vasquez describes how the development of tests by the 
philanthrocapitalist Carlos Slim’s Foundation in Mexico that detect risk of diabetes 
both transform’s people’s relationship to chronic disease risk while opening up new 
markets in public health. Ultimately, Vasquez implies, these tests are primarily 
designed for the generation of private financial—as opposed to public health—
value (cf. Hayden 2007).  
In a similar vein, Whitacre explores the bioeconomy of diagnostic testing for HIV, 
showing how HIV testing in public health research feeds into a drug development 
infrastructure, posing the question of whether confessional practices such as 
disclosure of test results should be considered as a form of labour. Vernooij 
similarly explores tensions between economic and public health value, though in 
this case in the context of profound infrastructural instability in Sierra Leone. 
Together with the Field Note by Bah, Vernooij, and Street, this research shows 
how the undervaluing of diagnostic work in Sierra Leonean health institutions leads 
to informal exchanges in which the value assigned to tests as sources of 
livelihoods takes priority over their life-saving capacities.  
In several of these cases, what appears to get lost in the marketisation of 
diagnostic tests is the question of what value a test might hold for the person being 
tested. Vasquez, for example, shows that a pre-diabetes diagnosis is essentially 
meaningless for patients as they would have received the same public health 
advice irrespective of the test result. Widmer’s Position Piece on direct-to-
consumer (DTC) microbiome tests points to how future users are imagined 
specifically not as patients, but instead as empowered consumers, driven by a 
commitment to self-knowledge and personal improvement, captivated by 
producers of new healthscapes that incorporate diverse forms of life in order to 
optimise wellbeing. The making of that producer/consumer—or what she terms 
‘prosumer’—is simultaneously a process of financial subjectification, as users 
provide biological materials to be prospected, often by for-profit companies.  
In those elisions between health citizenship and bioeconomy, however, Widmer 
sees potential: tests create the conditions for a microbiopolitics positioned against 
the public health, agricultural, and biomedical practices that underpin the dis-eases 
of contemporary capitalism. Even in situations where science is looking for a return 
on investment, we might ask what value tests hold for the people who develop, 
work with, or encounter them—a lived experience that is not always predictable or 
straightforward. 
Testing uncertainties 
The clinical and/or public health value of medical tests is often linked to the 
diagnostic certainty they can provide. Yet the sociology of diagnosis has long 
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highlighted the uncertainties and anxieties that diagnostic testing can generate, 
especially when deployed for the purpose of screening ‘healthy’ populations 
(Gillespie 2012; Armstrong and Eborall 2012; Timmermans and Buchbinder 2010; 
Lupton 2012). Several of the contributions to this special issue build on this insight 
by highlighting the uncertainties and ambivalences generated by medical testing. 
Arteaga Pérez’s analysis of new diagnostics based on biomarkers that could, at 
least in theory, predict tumour evolution provides insight into the scientific 
uncertainties that underpin the development of novel diagnostic tests. She shows 
the process of validating the ‘raw signals’ of future disease to be one fraught with 
ambiguities and requiring extensive labour and infrastructural investment. Once 
developed tests reach the point of use, as Janssen et al. discuss in their 
contribution to this issue, at which point, further uncertainties pertain as to whether 
to test, how a test is to be conducted, and whether its results are accurate, but also 
to broader ambivalences about the purposes and meanings of test results and their 
clinical, social, economic and personal consequences.  
In several contributions to this issue, diagnostic uncertainty is shown to generate 
anxiety and ambivalence for the persons undergoing testing. Janssen et al. explore 
the role of HIV oral self-testing in generating the at-risk subject, which they analyse 
through the concept of ‘living under HIV’, building on the conceptualisation of ‘living 
under diagnosis’ developed by Lenore Manderson in a previous MAT special 
section (Manderson 2020). In a high-prevalence setting where there is a high 
chance that a positive test result is a true positive, uncertainties around test 
conduct and interpretation are experienced as intensely stressful for participants—
an aspect of testing that gets lost in policy prescriptions around improving user 
conduct and compliance.  
The ethics of inhabiting those subject positions become perhaps even more 
fraught when the diagnosis is still to be determined. In the research article by 
Janssen et al. it is the at-risk status of individuals that makes them eligible for 
testing (or, as in the article by Whitacre, participation in public health research that 
involves testing). But in the context of predictive diagnostic testing it is risk itself 
that testing helps to diagnose. Drawing on Das’s notion of ordinary ethics, Frumer 
et al., for instance, explore the ways that monitoring for lung cancer following a 
pre-diagnosis poses ethical questions for patients about how to live a good life in 
the shadow of death, but also what ‘good’, if any, comes from the knowledge of 
their cancer risk, raising the prospect that medical tests may sometimes accrue 
negative value for those who receive their results. That state of anticipation can 
give an existential torque to mundane life, as patients are forced to undertake 
perpetual close readings of their individual bodies, attending to emerging signs of 
impending death and making attempts to forestall it. 
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Testing anxieties, as Price’s contribution shows, are also intensified when tests 
are assigned an authority that exceeds their biological capacities to generate 
meaningful results. There are many scientific reasons why a biomarker may not 
indicate the presence of an active infection. This is precisely why tests are usually 
only one aspect of the diagnostic process and require expert interpretation. Yet 
governmental bureaucracies are often highly constrained in their capacity to 
accommodate these ambiguities and instead short-circuit the diagnostic process 
to conflate test result with diagnostic label. As Price demonstrates, in the case of 
people who receive ‘persistent positives’ for SARS-CoV-2 infection, the 
‘disconnect between the biological and the biopolitical’ can have far reaching 
repercussions for livelihoods and wellbeing.  
Towards an anthropology of medical testing: Diagnostic 
pragmatics  
As a whole, the collection speaks to the multivalent nature of medical testing. We 
encounter situations in which tests are deployed as research tools (Whitacre; 
Arteaga Pérez); as tools of epidemic control (Löwy; Beaudevin et al.); as 
instruments of subjectification and citizenship (Price; Janssen et al.; Widmer); as 
the genus of epidemiological reason and aporia in clinical care (Bunkley; Bah, 
Vernooij, and Street); as sites of economic exchange (Vasquez; Vernooij); and as 
exercises in governmentality and extensions of sovereign power (Chowdhury and 
Basu; Frumer et al.; Kameda). The multiple purposes to which medical tests can 
be put highlights the importance of a dedicated anthropology of medical testing, as 
opposed to testing being subsumed into the anthropology or sociology of 
diagnosis. But beyond an invitation to ethnographic scrutiny, the fundamental 
elasticity of testing—moving from laboratory bench to bedside, and from 
boardroom to courthouse and houses of parliament—also raises important 
questions about fundamental discrepancies in the expectations that testing 
generates, and in the work tests are being asked to do, for whom, by whom, and 
to what specific ends.  
A concern with the pragmatics of testing cuts across these contributions which, 
when considered together, provide the opportunity to follow the production of 
social, medical, political, and economic realities at the point where diagnostic 
devices are deployed and testing is performed. Those enactments transcend the 
moment of clinical diagnosis, making disease doable across a variety of contexts 
and scales, creating new avenues for action, opening up possibilities for 
intervention while foreclosing others (Fujimura 1987). As Vasquez (this issue) 
deftly puts it, diagnostics help to define ‘what constitutes actionable risk and for 
what public health action should aim to achieve’.  
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What is doable, of course, is not always what should be done; and it is on testing’s 
normative orientation that Rosengarten focuses her concern. Drawing from 
speculative process philosophy, Rosengarten seeks to recentre the sentience, 
creativity, and labour of individual bodies on the production of biological 
knowledge. If, as she argues in her Position Piece, we repopulate a singular 
diagnosis with somatic signs and intelligence, which are necessary to render 
disease visible, then we can repair often violent abstractions of diagnostic 
taxonomies and reconnect biomedical categories to the lived experiences of the 
patient. Extending the commitments of a pragmatic tradition, Rosengarten 
suggests how we can begin to read value as immanent to medical realities, rather 
than as the commitments, perspectives, and concerns that precede that arrival at 
a biological fact. Perhaps this is ultimately where an anthropology of testing can 
provide most traction—in holding in abeyance the compulsion to ‘test, test, test’ 
long enough to consider the normative valence of the interventions those tests 
precipitate. Rather than criteria of diagnostic accuracy, ethnographies of testing in 
context offer pathways for considering the complex consequences of testing—
representing new trajectories along which tests can be evaluated by the resources 
they offer for deliberation over the nature of public good. 
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